Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ADVENTRX Pharmaceuticals Inc (Anx) -- Ignore unavailable to you. Want to Upgrade?

To: Keith Feral who wrote (174)	6/14/2007 6:22:17 PM
From: estatemakr	Respond to of 418

The "Length of time = Success" ratio of the 2B trials should be known and fairly obvious to astute/significant investors in ANX, therefore, it may partially explain the steady uptrend since mid-March, and one could also anticipate that the stock may continue to rise steadily as time marches on while results fail to surface....... One would also surmise that folks like AMGN also are keenly aware of this factoid. Somewhat akin to a game of chicken, no?

To: Keith Feral who wrote (174)	6/15/2007 12:37:17 PM
From: Keith Feral	Respond to of 418

I typed the wrong year in my prior post. Fact - US phase 2 began dosing on May 4, 2005 and announced positive results on January 25, 2006. Bottom line, it only took 9 months to complete the entire study from start to finish. They announced further resutls in March 2006. Fact - European Phase 2 b trials began on May 31, 2005 and enrollment was completed on Sept 25, 2006. As of June 14, 2007 there are patients still on protocol. The last patients have been on protocol for 9 months now. To me, it's quite obvious these trials are going much better for Adventrx, measured by the length of time the patients have been responding to treatment. I can only assume that the successful treatment of these patients into the 9th month of monotherapy is a great thing for Cofactor. We all need to start thinking about how good it is to wait for the data. The longer we wait, the better the ttp, response rate and other preliminary data including the toxicity results. We can only assume it's a win win for efficacy and toxicity at this point.